CTI BioPharma Corp. (CTIC)

NASDAQ: CTIC · IEX Real-Time Price · USD
5.77
+0.13 (2.30%)
Sep 27, 2022 4:00 PM EDT - Market closed
2.30%
Market Cap 660.00M
Revenue (ttm) 14.62M
Net Income (ttm) -120.80M
Shares Out 114.39M
EPS (ttm) -1.23
PE Ratio n/a
Forward PE 26.60
Dividend n/a
Ex-Dividend Date n/a
Volume 1,840,526
Open 5.73
Previous Close 5.64
Day's Range 5.56 - 5.78
52-Week Range 1.43 - 7.80
Beta 0.88
Analysts Buy
Price Target 10.95 (+89.8%)
Earnings Date Nov 10, 2022

About CTIC

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed ... [Read more...]

Industry Biotechnology
IPO Date Mar 21, 1997
CEO Adam Craig
Employees 121
Stock Exchange NASDAQ
Ticker Symbol CTIC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for CTIC stock is "Buy." The 12-month stock price forecast is 10.95, which is an increase of 89.77% from the latest price.

Price Target
$10.95
(89.77% upside)
Analyst Consensus: Buy
Stock Forecasts

News

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , Sept. 21, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced the grant of equity awards to two new employees as equity inducement awards outside of the Company's Amended a...

5 days ago - PRNewsWire

CTI BioPharma Announces Presentation of New Anemia Benefit Data from Pacritinib Program at the Society of Hematologic...

SEATTLE , Sept. 21, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced two poster presentations from the Company's pacritinib program at the Society of Hematologic Oncology (SOHO) T...

5 days ago - PRNewsWire

Why CTI BioPharma Stock Got Rocked on Tuesday

Woe betide any company that reports even a narrow bottom-line miss on quarterly results these days.

1 month ago - The Motley Fool

CTI BioPharma (CTIC) Reports Q2 Loss, Tops Revenue Estimates

CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5% and 20.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

CTI BioPharma Reports Second Quarter 2022 Financial Results

– VONJO® (pacritinib) net product revenue of $12.3 million in the second quarter – – Management to host conference call today at 4:30 p.m. ET – SEATTLE , Aug. 8, 2022 /PRNewswire/ -- CTI BioPharma Corp....

1 month ago - PRNewsWire

CTI BioPharma to Report Second Quarter 2022 Financial Results on August 8, 2022

– Company Also Announces Participation in the BTIG Biotechnology Conference and the Stifel Biotech Summer Summit – SEATTLE , Aug. 1, 2022 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTI...

1 month ago - PRNewsWire

Why CTI BioPharma Stock Blasted 18% Higher Today

An analyst launches coverage of the company with an unequivocal buy recommendation.

2 months ago - The Motley Fool

CTI BioPharma Presents Pivotal Data from Pacritinib Program at the European Hematology Association (EHA) 2022 Congress

SEATTLE , June 10, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced two scientific poster presentations from the Company's pacritinib clinical program at the European Hematology A...

3 months ago - PRNewsWire

CTI BioPharma to Present at Upcoming June Conferences

SEATTLE , June 2, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at two upcoming investor conferences in New York City. Present...

3 months ago - PRNewsWire

CTI BioPharma Presents Pivotal Data from Pacritinib Program at the 2022 American Society of Clinical Oncology Annual ...

SEATTLE , May 26, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced a poster presentation from the Company's pacritinib program at the 2022 American Society of Clinical Oncology (A...

4 months ago - PRNewsWire

Why CTI Biopharma Stock Is Surging Today

A strong launch for the company's first commercialized drug drew a cheer from investors.

4 months ago - The Motley Fool

CTI BioPharma (CTIC) Reports Q1 Loss, Tops Revenue Estimates

CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5.71% and 6.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

CTI BioPharma Reports First Quarter 2022 Financial Results

– Strong U.S. commercial launch of VONJO™  (pacritinib) underway following accelerated FDA approval for the treatment of adult patients with Myelofibrosis and Thrombocytopenia – – VONJO (pacritinib) net...

4 months ago - PRNewsWire

CTI BioPharma Announces Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

SEATTLE , May 10, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced one poster presentation from the Company's pacritinib program at the 2022 American Society of Clinical Oncology ...

4 months ago - PRNewsWire

CTI BioPharma to Report First Quarter 2022 Financial Results on May 12, 2022

SEATTLE , April 28, 2022 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its first quarter 2022 financial results on Thursday, May 12, ...

4 months ago - PRNewsWire

NCCN Guidelines® Recommend VONJO™ (pacritinib) for the Treatment of Myeloproliferative Neoplasms

VONJO is the only approved JAK inhibitor recommended by NCCN for myelofibrosis patients regardless of platelet count SEATTLE , April 14, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today ann...

5 months ago - PRNewsWire

CTI BioPharma to Present at the 21st Annual Needham Virtual Healthcare Conference

SEATTLE , April 6, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference at...

5 months ago - PRNewsWire

CTI BioPharma (CTIC) Reports Q4 Loss, Lags Revenue Estimates

CTI BioPharma (CTIC) delivered earnings and revenue surprises of -35.71% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

CTI BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results

– VONJOTM (pacritinib) Approved by FDA for the Treatment of Adult Myelofibrosis Patients with Myelofibrosis and Thrombocytopenia; Commercial Launch Underway – – $60 Million Payment from DRI Healthcare T...

5 months ago - PRNewsWire

Should You Buy CTI BioPharma (CTIC) After Golden Cross?

Is it a good or bad thing when a stock experiences a golden cross technical event?

6 months ago - Zacks Investment Research

CTI BioPharma to Present at the Cowen 42nd Annual Healthcare Conference

SEATTLE, March 2, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cowen Annual Healthcare Conference at 1:30 p.m. ET. The...

6 months ago - PRNewsWire

CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myel...

SEATTLE, Feb. 28, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. Food and Drug Administration (FDA) has approved VONJO (pacritinib) for the treatment of adults with int...

6 months ago - PRNewsWire

CTI BioPharma Presents Data from Pacritinib Program at the 63rd American Society of Hematology Meeting

SEATTLE, Dec. 13, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) announced five scientific poster presentations on the pacritinib clinical program at the 63rd American Society of Hematology (AS...

9 months ago - PRNewsWire

CTI BioPharma to Present at the JMP Securities Hematology & Oncology Summit on Monday, December 6

SEATTLE, Dec. 2, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Hematology & Oncology Summit at 3:40 p.m....

9 months ago - PRNewsWire

Why CTI BioPharma Stock Is Plunging Today

The FDA extended its review period for myelofibrosis candidate pacritinib.

9 months ago - The Motley Fool